Screening optimal candidates with operable, early-stage triple-negative breast cancer benefitting from capecitabine maintenance: A post-hoc analysis of the SYSUCC-001 study.

MLA

Duan, Fangfang, et al. “Screening Optimal Candidates with Operable, Early-Stage Triple-Negative Breast Cancer Benefitting from Capecitabine Maintenance: A Post-Hoc Analysis of the SYSUCC-001 Study.” Breast, vol. 76, Aug. 2024, p. N.PAG. EBSCOhost, https://doi.org/10.1016/j.breast.2024.103740.

APA

Duan, F., Hua, X., Bi, X., Wang, S., Shi, Y., Xu, F., Wang, L., Huang, J., Yuan, Z., & Huang, Y. (2024). Screening optimal candidates with operable, early-stage triple-negative breast cancer benefitting from capecitabine maintenance: A post-hoc analysis of the SYSUCC-001 study. Breast, 76, N.PAG. https://doi.org/10.1016/j.breast.2024.103740

Chicago

Duan, Fangfang, Xin Hua, Xiwen Bi, Shusen Wang, Yanxia Shi, Fei Xu, Li Wang, Jiajia Huang, Zhongyu Yuan, and Yuanyuan Huang. 2024. “Screening Optimal Candidates with Operable, Early-Stage Triple-Negative Breast Cancer Benefitting from Capecitabine Maintenance: A Post-Hoc Analysis of the SYSUCC-001 Study.” Breast 76 (August): N.PAG. doi:10.1016/j.breast.2024.103740.